NRx Pharmaceuticals gets FDA approval for NRX-101 protocol
Share
- NRx Pharmaceuticals received FDA authorization for an expanded access program for its depression treatment drug candidate.
- Following the announcement, the company's shares increased to trade up at $4.03.
- The company initiated its pivotal clinical trial across civilian and military settings to evaluate treatment efficacy.
NRx Pharmaceuticals (NASDAQ:NRXP) secured FDA authorization for a depression treatment protocol with an initial drug cost of $0.
This compassionate care decision allows treatments outside of standard clinical trials compared to more restrictive limits in previous years.
The company stated that physicians can obtain the medication with patients only paying for shipping and mandatory data collection fees.
This development follows the business pricing an underwritten public offering of over five million common stock shares at $3.50.
Additionally, the firm reduced its first-quarter net loss for 2026 down to $1.4 million to reach debt-free financial status.
